Recently, trimebutine maleate was studied for the treatment of ovarian cancer and has shown positive results in preventing ovarian cancer recurrence and drug resistance both in vivo and in vitro via BK channel inhibition [123]. This evidence concerns the gene KCNMA1 and ovarian carcinoma.